Eben L Rosenthal

US Patent:

20130261444, Oct 3, 2013

Filed:

Mar 15, 2013

Appl. No.:

13/841259

Inventors:

Sergey B. Mirov - Vestavia Hills AL, US
Eben L. Rosenthal - Birmingham AL, US
Paul Castellanos - Vestavia Hills AL, US
Dmitry V. Martyshkin - Birmingham AL, US

International Classification:

A61N 5/06
B05D 3/10

US Classification:

600431, 604 20, 604501, 427 21

Abstract:

Methods, structures, devices and systems are disclosed for implementing a photothermal therapy using nanostructures. In one aspect, a device to produce a photothermal effect includes a particle having a molecular layer functionalized onto the external surface of the particle and structured to attach to one or more targeting molecules capable of binding to a receptor site of a cell, in which the particle is configured to absorb light energy at a particular wavelength to produce a plasmon resonance effect that causes the particle to emit heat energy. In some implementations, the device is deployed in an organism having a tumor that includes a plurality of the cell and binds to the receptor site of the tumor by the targeting molecules, in which the light energy is emitted at a region of the organism that contains the tumor and the heat energy causes cellular death of the tumor cell.

US Patent:

20220323616, Oct 13, 2022

Filed:

Jul 7, 2020

Appl. No.:

17/625224

Inventors:

- Stanford CA, US
William R. Goodyer - Stanford CA, US
Benjamin Beyersdorf - Stanford CA, US
Nynke Van Den Berg - Stanford CA, US
Eben Rosenthal - Stanford CA, US

International Classification:

A61K 49/00
C07K 16/18
A61K 47/68
A61K 47/69
C12N 5/077
G01N 33/58

Abstract:

Antibodies which bind selectively to cardiac conduction system (CCS) cells, imaging and/or diagnostic reagents and compositions visualizing the CCS cells and therapeutic products and compositions comprising one or more of the antibodies. Methods for delivering therapeutic agents to the CCS cells. The disclosure further provides methods for visualizing the CCS cells in vivo in real time, including in a subject undergoing a cardiothoracic surgery or other cardiac intervention. Compositions and methods for isolation, purification, analyses and/or transplantation of the CCS cells, including pluripotent stem cell (hiPSC)-derived or human embryonic stem cell (hESC)-derived CCS cells.